AMARIN CORP PLC\UK (AMRN)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$129.7M
Cash & Equivalents
$6.4M
Quarterly Burn Rate
$317M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06637657 Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD OTHER Recruiting 5,586
NCT03428477 EPA for Metastasis Trial 2 PHASE3 Active Not Recruiting 418

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for AMRN.

SEC EDGAR Filings

All SEC filings for AMARIN CORP PLC\UK on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.